The World Health Organization says a clinical trial has started in the Democratic Republic of Congo to test two potential treatments for the Bundibugyo species of Ebola, which has been driving an outbreak in the country’s northeastern provinces. WHO reports that there are currently no approved vaccines or treatments for this rare strain. WHO figures cited in the coverage indicate 1,406 confirmed cases and 438 confirmed deaths in the DRC, with 208 recoveries reported. WHO Director-General Tedros Adhanom Ghebreyesus says the trial begins with the enrollment of the first patient and evaluates the monoclonal antibody MBP134 and the antiviral drug remdesivir, tested alone and in combination. The study is conducted by the DRC’s National Institute for Biomedical Research with support from partners including the WHO. The organization says participants receive comprehensive supportive care and close follow-up during the trial, and that efforts are underway to ensure access to the two drugs if they are found safe and effective.